The influence of HCQ on LPD in patients with RA is unclear; however, Zhang et al. found that in a retrospective study of patients with systemic lupus erythematosus—another rheumatic disease positive for anti-Ro/SS-A antibodies at a certain rate—fewer patients with hematological malignancies, including lymphoma, took HCQ compared to those without hematological malignancies [50]. The gene discussed is RO60; the disease is rheumatoid arthritis.